

AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

Please cancel claims 41, 42, 44-46, 48-50, 65, 66, 68 and 69 without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims

Claims 1-55 (Canceled)

Claim 56 (Previously presented): A pharmaceutical composition comprising retinal pigment epithelial (RPE) cells, a non-RPE cell population, and a pharmaceutically acceptable carrier, wherein said non-RPE cell population comprises insulin-producing β cells.

Claim 57 (Previously presented): The composition of claim 56 wherein said insulin-producing β cells are pancreatic islet of Langerhans cells.

Claims 58-61 (Canceled)

Claim 62 (Previously presented): A compartmentalized kit adapted to receive a first container adapted to contain retinal pigment epithelial (RPE) cells and a second container adapted to contain a non-RPE cell population, wherein the non-RPE cell population comprises insulin-producing β cells.

Claim 63 (Previously presented): The compartmentalized kit according to claim 62, wherein the insulin-producing β cells are pancreatic islet of Langerhans cells.

Claim 64-69 (Canceled)

Claim 70 (Previously presented): The composition of claim 56 wherein said RPE cells are attached to a matrix.

Claim 71 (Previously presented): The composition of claim 56 wherein cells of said population of non-RPE cells are attached to a matrix.

Claim 72 (Previously presented): An article of manufacture, comprising:
a packaging material;
retinal pigment epithelial (RPE) cells containing within said packaging material;
a non-RPE cell population contained within said packaging material, wherein the non-RPE cell population comprises insulin-producing β cells; and
wherein said packaging material contains a label that indicates that said RPE cells can be used for facilitating survival of an allogeneic graft of the non-RPE cell population in a mammal.

Claim 73 (Previously presented): The article of manufacture according to claim 72, wherein the insulin-producing β cells are pancreatic islet of Langerhans cells.